Mild hypothermia in deceased organ donors significantly reduces delayed graft function in kidney transplant recipients when compared to normal body temperature, according to UCSF researchers and collaborators, a finding that could lead to an increase in the availability of kidneys for transplant.
Following several years of research and collaboration, physicians and engineers at Johns Hopkins and Walter Reed National Military Medical Center say they have developed a computer platform that provides rapid, real-time feedback before and during facial transplant surgery, which may someday improve face-jaw-teeth alignment between donor and recipient.
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating patients with a form of cardiomyopathy called restrictive cardiomyopathy (RCM).
Surgeons at The Children’s Hospital of Philadelphia (CHOP) joined with colleagues from Penn Medicine recently to complete the world’s first bilateral hand transplant on a child. Earlier this month, the surgical team successfully transplanted donor hands and forearms onto eight-year-old Zion Harvey who, several years earlier, had undergone amputation of his hands and feet and a kidney transplant following a serious infection.
The average wait time for a kidney transplant is five years and there are more than 100,000 people on the waiting list. However, there are thousands of viable hepatitis C-positive kidneys that are discarded each year solely because they’re infected. A new perspective paper in The New England Journal of Medicine suggests that “new antiviral therapies with cure rates exceeding 95 percent should prompt transplant-community leaders to view HCV (hepatitis C virus)-positive organs as a valuable opportunity for transplant candidates with or without pre-existing HCV infection.”
A deceased donor liver has been preserved and kept healthy outside the body in a device that mimics the body’s physiological functions and successfully transplanted into a human, for the first time in Ontario.
Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure.
As bone marrow and lung stem cells are quite similar, the Weizmann Institute’s Prof. Yair Reisner investigated whether transplant methods used for bone marrow might also work for treating lung diseases such cystic fibrosis and asthma. When mice with lung damage were given the new stem cell treatment, their lungs healed and breathing improved.
Organ transplant rejection in hosts that were previously tolerant may not be permanent. Using a mouse model of cardiac transplantation, scientists from the University of Chicago found that immune tolerance can spontaneously recover after infection-triggered rejection, and that hosts can accept subsequent transplants as soon as a week after.
The McMaster team recruited 75 patients with a flare up of their ulcerative colitis and randomized them to fecal transplant therapy given as an enema derived from stool donated by an anonymous healthy donor, and placebo.
The University of Kansas Cancer Center’s Bone Marrow Transplant program is participating in a nationwide clinical trial that analyzes outcomes after two common treatments: bone marrow transplant and chemotherapy. The results could lead to wider access to transplants.
Two studies demonstrate that hyperlipidemia (high cholesterol and high triglycerides in the blood) caused by a high-fat diet accelerates heart-transplant rejection in mice. The researchers from Tufts University School of Medicine also found that simply feeding mice a high-fat diet increased organ rejection.
Ten years after undergoing a heart-lung transplant, Andrew Gaumer is looking forward to first Father’s Day. Andrew's wife gave birth to their first child on Mother's Day.
Aging can cause many changes to the body, including obesity and a loss of lean mass. Now, a group of University of Florida Health researchers has discovered that an existing drug reduces body fat and appetite in older rats, which has intriguing implications for aging humans.
A joint investigation including UT Southwestern Medical Center has found a molecule that may play a significant role in accelerating cell recovery following bone marrow transplants, liver disease, and colon disease.
In a study published in Science June 12, Case Western Reserve and University of Texas-Southwestern researchers detail how a new drug repaired damage to the colon, liver and bone marrow in animal models — even saving mice who otherwise would have died in a bone marrow transplantation model.
Blood and Marrow Transplantation (BMT) is a potentially curative treatment for patients with leukemia or other life-threating blood diseases. With a goal of increasing survival rates, a research team led by Roswell Park Cancer Institute (RPCI) investigators verified patient outcome data submitted by more than 150 U.S. transplant centers over an 11-year period to the Center for International Blood and Marrow Transplant Research (CIBMTR). The detailed investigation — published in the journal Biology of Blood and Marrow Transplantation — offers insight into different causes of death. The results of this genome-wide association study led to the development of a first-of-its-kind definition of specific causes of mortality after unrelated-donor, or allogeneic, BMT.
Older patients who received stem cells from younger, unrelated donors with higher numbers of so-called killer T cells (CD8 cells) had significantly reduced risk of disease relapse and improved survival compared to those who received stem-cells from donors with low numbers of CD8 cells, including older matched siblings.